ACD Pharmaceuticals

ACD Pharma is a Norwegian biotechnology company specializing in the development of bacteriophage-based solutions for the aquaculture industry. As a pioneer in phage therapy, the company focuses on reducing the reliance on antibiotics in fish farming by targeting specific pathogenic bacteria such as those causing winter sores and vibriosis. Their lead commercial product line, CUSTUS, utilizes naturally occurring phages to maintain fish health and welfare in a sustainable manner. ACD Pharma operates as the research and development arm of the Nordly Holding group, leveraging a proprietary platform for phage isolation and characterization. The company is also exploring the potential application of its phage technology in human medicine and other animal health sectors. By providing targeted antimicrobial treatments, ACD Pharma aims to address the global challenge of antibiotic resistance while improving productivity in global food systems.